Biopharma & Life Sciences
Quanterix Executive Compensation (FY25)
QTRX · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 10, 2026
160 figures on this page: 155 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Masoud Toloue: $6,433,027 → $5,250,745 (18.4% lower)
Frequently asked questions
Answers drawn from the data on this page.
What was Quanterix's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 87.7% of votes cast for or against in favor at the meeting held June 9, 2026.
Which companies are in Quanterix's peer group?
The disclosed peer group includes 10X Genomics, Adaptive Biotechnologies Corporation, Castle Biosciences, Inc., Cryoport, Inc. and Cytek Biosciences, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Masoud Toloue Former President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Vandana Sriram Chief Financial Officer and Treasurer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Masoud Toloue Former President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Vandana Sriram Chief Financial Officer and Treasurer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Masoud Toloue Former President and Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Vandana Sriram Chief Financial Officer and Treasurer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
William Donnelly Former Executive Chair Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Masoud Toloue | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Masoud Toloue | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Vandana Sriram | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Vandana Sriram | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| William P. Donnelly | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| William P. Donnelly | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| William P. Donnelly | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Vandana Sriram | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Scott Mendel | ◇ | ◇ | ◇ | — | — | — | ◇ |
Myla Lai-Goldman, M.D | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Garret M. Hampton, Ph.D | ◇ | ◇ | — | — | — | ◇ | ◇ |
Alan Sachs, M.D., Ph.D | ◇ | ◇ | — | — | — | ◇ | ◇ |
Jeffrey T. Elliott Lead independent director | ◇ | ◇ | ◇ | — | — | — | ◇ |
Karen A. Flynn | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Ivana Magovevcic-Liebisch, Ph.D., J.D | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Paul M. Meister | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
David R. Walt, Ph.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Martin D. Madaus, Ph.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Sarah E. Hlavinka | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
William P. Donnelly and Everett Cunningham served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board equity retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- 10X Genomics TXG
- Adaptive Biotechnologies Corporation ADPT
- Castle Biosciences, Inc. CSTL
- Cryoport, Inc. CYRX
- Cytek Biosciences, Inc. CTKB
- Maravai LifeSciences Holdings, Inc. MRVI
- Mesa Laboratories, Inc. MLAB
- Nautilus Biotechnology, Inc. NAUT
- OmniAb, Inc. OABI
- Pacific Biosciences of California, Inc. PACB
- Quantum-Si Incorporated QSI
- Standard BioTools Inc. LAB
- Twist Bioscience Corporation TWST
- Veracyte, Inc. VCYT
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 9, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | September 29, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 3, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 7, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 23, 2022 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Quanterix disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Quanterix sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
160 figures on this page: 155 cited to the filing that reported them, 5 calculated from figures it prints.
155 cited to the filing
5 calculated from the filing
Documents cited
- 0001503274-26-000028Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-26-048166EXECUTIVE OFFICER AND DIRECTOR COMPENSATION · Executive Officer and Director Compensation · Outstanding Equity Awards at 2025 Fiscal Year-End · Summary Compensation Table · and 1 more section
- 0001503274-25-000097
- 0001104659-25-082586Summary Compensation Table
- 0001104659-24-069615Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-24-047245Summary Compensation Table
- 0001104659-23-069375Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-22-074770Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Quanterix executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/QTRX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Quanterix and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Quanterix discloses
The companies named in QTRX's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}